Affiliations 

  • 1 Dubai Hospital, Mohamed Bin Rashed University, United Arab Emirates. Electronic address: mhassanein148@hotmail.com
  • 2 Research Department, Baqai Institute of Diabetology and Endocrinology, Baqai Medical University, Karachi, Pakistan. Electronic address: sanobia93@gmail.com
  • 3 Baqai Institute of Diabetology and Endocrinology, Baqai Medical University, Karachi, Pakistan. Electronic address: myakoob@bide.edu.pk
  • 4 Dubai Hospital, Dubai, University of Sharjah UAE, United Arab Emirates. Electronic address: alaaeldin11@gmail.com
  • 5 Internal Medicine and Diabetes, Faculty of Medicine, Cairo University, Egypt. Electronic address: Inassshaltout@hotmail.com
  • 6 Endocrine Centre, RIPAS Hospital, Brunei Darussalam. Electronic address: alice.yong@moh.gov.bn
  • 7 Diabetes Unit, Department of Medicine, Rashid Hospital, Dubai Academic Health Corporation, Saudi Arabia. Electronic address: khadija.hafidh@gmail.com
  • 8 Department of Internal Medicine, Hospital Putrajaya, Putrajaya, Malaysia. Electronic address: zanariahh@hotmail.com
  • 9 King Fahad Medical City, OEMC Department, Alriyadh, Saudi Arabia. Electronic address: mkallash@kfmc.med.sa
  • 10 Obesity, Endocrine and Metabolic Center, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia. Electronic address: njaljohani@kfmc.med.sa
  • 11 Division of Endocrinology, Department of Internal Medicine, Hospital Tengku Ampuan Rahimah, Klang, Selangor, Malaysia. Electronic address: cerylwhuch@gmail.com
  • 12 Professor of Internal Medicine, Medistate Kavaick Hospital, ISTANBUL, Turkey. Electronic address: akif_buyukbese@yahoo.com
  • 13 Department of Diabetes and Metabolism, The Royal London Hospital, Whitechapel, London, UK. Electronic address: tahseen.chowdhury@nhs.net
  • 14 University of Tizi Ouzou Algeria, CES Diabetology University of Sétif, Algeria. Electronic address: merzoukififa@gmail.com
  • 15 Simpang Kuala Health Clinic, Alor Setar Kedah, Malaysia. Electronic address: sriwahyu2006@yahoo.com.my
  • 16 Endocrinologist - Diabetologist, Rabat, Morocco, President of Moroccan League for the Fight Against Diabetes, Chair of IDF Mena Region. Electronic address: jamalbelkhadir@yahoo.fr
  • 17 Ferhat Abbas Setif University, Algeria. Electronic address: Rmalekdz@gmail.com
  • 18 Endocrinology Unit, Department of Medicine, Sultanah Bahiyah Hospital, Alor Setar, Malaysia. Electronic address: adyania@yahoo.com
  • 19 Saifee Hospital, Mumbai, Treasurer Maharashtra ESI Executive Committee Member ESI, India. Electronic address: drshehlas@gmail.com
  • 20 Department of Medicine, Alzahra College of Medicine, University of Basrah, Iraq. Electronic address: majid.alabbood@uobasrah.edu.iq
Diabetes Metab Syndr, 2023 Jul;17(7):102799.
PMID: 37301008 DOI: 10.1016/j.dsx.2023.102799

Abstract

BACKGROUND AND AIMS: The DaR Global survey was conducted to observe the impact of the COVID-19 pandemic on the intentions to fast and the outcomes of fasting in people with diabetes and chronic kidney disease (CKD).

METHODS: Muslim people with diabetes and CKD were surveyed in 13 countries shortly after the end of Ramadan 2020, using a simple Survey Monkey questionnaire.

RESULTS: This survey recruited 6736 people with diabetes, of which 707 (10.49%) had CKD. There were 118 (16.69%) people with type1 diabetes (T1D), and 589 (83.31%) were with type2 diabetes (T2D). 62 (65.24%) people with T1D and 448 (76.06%) people with T2D had fasted with CKD. Episodes of hypoglycaemia and hyperglycaemia were more frequent among people with T1D compared to T2D, 64.52% and 43.54% vs 25.22% and 22.32% respectively. Visits to the emergency department and hospitalization were more frequent among people with CKD, however no significant difference was found between people with T1D and T2D.

CONCLUSION: The COVID-19 pandemic had only a minor effect on the intention to fast during Ramadan in people with diabetes and CKD. However, hypoglycaemia and hyperglycaemia were found to be more frequent, as well as emergency visits and hospital admissions among people with diabetic kidney disease. Prospective studies are needed in future to evaluate the risk indicators of hypoglycaemia and hyperglycaemia among fasting people with CKD, especially in the context of different stages of kidney disease.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.